ANGEL2

Across TCGA pan-cancer cohorts, ANGEL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANGEL2 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANGEL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANGEL2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, UCEC, and GBM are the cancer types where ANGEL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.952	0.633	<.001	47	view →
UCEC	OS	Quartile	III,IV	0.368	1.000	.010	32	view →
GBM	DFS	Quartile	All	0.895	0.598	.014	10	view →
COAD	DFS	Median	III,IV	0.619	1.000	.049	6	view →
LSCC	DFS	Median	All	0.627	0.916	.035	3	view →
CCRCC	OS	Median	All	0.902	0.780	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANGEL2–LUAD (OS)

Open the LUAD breakdown →